Intranasal placebo

Phase 2

WWake Forest University Health Sciences

Intranasal placebo is one of 26 therapeutic programs targeting Type 2 Diabetes. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Type 2 DiabetesRecruiting

Pain, AcuteCompleted

Type 2 DiabetesPreclinical

Recruiting

Pain, AcutePhase 2

Completed

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

NOVOLIN R

Novo Nordisk

Preclinical

5 2

Glargine

Eli Lilly

Preclinical

8 3

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 4

Intranasal placebo

WWake Forest University Health Sciences

Phase 2

1 5

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 6

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 7

Lovaza

AstraZeneca

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 10

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Type 2 Diabetes

NCT07675499

Clinical

Trials by Indication[1]

Type 2 Diabetes1 trial

Effects of Intranasal Insulin Plus Exercise Training on Brain Blood Flow, Neuronal Insulin Signaling, and Cognition in Adults With Type 2 Diabetes

Recruiting·RRutgers, The State University of New Jersey·Preclinical·NCT07675499·60 enrolled

Pain, Acute1 trial

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain

Completed·WWake Forest University Health Sciences·Phase 2·NCT07053774·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Intranasal placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Intranasal placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Wake Forest University Health Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: WWake Forest University Health Sciences

Intranasal placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Type 2 Diabetes1 trial

Pain, Acute1 trial

References

Drug Info

Quick Facts

Related News